Boston Scientific price target raised to $71 from $65 at Citi

Citi raised the firm’s price target on Boston Scientific to $71 from $65 and keeps a Buy rating on the shares. The company reported “strong” Q4 results, the analyst tells investors in a research note. The firm says the announcement of Farapulse FDA approval, the discussion of Farapulse in China and Japan in the second half of 2024, and the breadth of Boston Scientific’s portfolio “that made the quarter.”